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Background: Irreversible electroporation (IRE) has recently been added as an additional therapeutic ablative option
in patients with locally advanced cancers (LAC) involving vital structures. IRE delivers localized electric current by
peri-tumoral discrete probes to attain irreversible changes in cell membrane leading to cell death. The aim of this
study was to evaluate the long-term effects of IRE in the treatment of locally advanced tumors.
Methods: A prospective IRB approved evaluation of 107 consecutive patients from 7 institutions with tumors that
had vascular invasion treated with IRE from 5/2010 to 1/2012. LAC was defined as primary tumor with <5 mm from
major vascular structure based on pre-operative dynamic imaging or intra-operative criteria.
Results: IRE as utilized in LAC in the liver (N = 42, 40%) and pancreas (N = 37, 35%), with a median number of
lesions being 2 with a mean target size of 3 cm. IRE attributable morbidity rate was 13.3% (total 29.3%) with
high-grade complications seen in 4.19% (total 12.6%). No significant vascular complications were seen, and of the
high-grade complications, bleeding (2), biliary complications (3) and DVT/PE (3) were the most common. Complications
were more likely with pancreatic lesions (p = 0.0001) and open surgery (p = 0.001). Calculated local recurrence free
survival (LRFS) was 12.7 months with a median follow up of 26 months censured at last follow up. The tumor
target size was inversely associated with recurrence free survival (b = 0.81, 95% CI: 1.6 to 4.7, p value = 0.02) but
this did not have a significant overall survival impact.
Conclusions: IRE represents a novel therapeutic option in patients with LAC involving vital structures that are not
amenable to surgical resection. Acceptable to high local disease control and the long LRFS can be achieved with
this therapy in combination with other multi-disciplinary therapies.
Keywords: Irreversible electroporation, Locally advanced tumors, Vascular invasion, Liver tumors, Pancreatic
tumors, SafetyBackground
Electroporation is a phenomenon by which cell mem-
brane integrity is compromised by inducing nanopores
using trans-membrane electrical distortion. This was
initially used to increase the permeability of the cells to
therapeutic compounds and gene transfer in a reversible
fashion [1]. Subsequently, it was used as an independent
modality to achieve permanent cell destruction (irreversible* Correspondence: Robert.Martin@louisville.edu
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unless otherwise stated.electroporation) and demonstrated viability in cell, animal
and later human models [2]. These studies confirmed that
cell death occurred without breaching structural integrity
and leaving vascular structures unharmed [3].
We and other authors have recently demonstrated the
safety of the use of IRE around vascular and ductile struc-
tures on chronic large animal models [4-6]. Subsequent to
those studies we have recently published organ specific
safety and efficacy data with the use of IRE in liver and
pancreas [7-9]. As with any novel technology in clinical
practice, initial experience can be used to tailor subse-
quent indications, applications and strategies to limit the
morbidity of the procedure. We present our multi-centerLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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who underwent IRE of soft tissue tumors with vascular
invasion that were not amenable to surgical resection,
thermal ablation and/or had failed radiation therapy.
Methods
A prospective University of Louisville Institutional Review
Board approved multi-institutional registry including
University of Louisville Department of Surgery Division
of Surgical Oncology, the Department of Interventional
Radiology Baptist Hospital Little Rock AK, and The De-
partment of Interventional Radiology INOVA Alexandria
VA of consecutive patients undergoing IRE from 2010
through 2012 was reviewed. Additional sites that provide
data were Cleveland Clinic Cleveland OH, Roper St
Francis Hospital Charleston SC, Henry Ford Hospital
Detroit MI, Stony Brook University Long Island NY.
Ethical approval was obtained from all participating in-
stitutions. All patients provided written informed con-
sented to include their data in this prospective data
collection protocol. Inclusion criteria for this study in-
cluded the presence of peri-vascular invasion of primary
tumor (defined as tumor <5 mm from major vascular
structure) based on pre-operative dynamic imaging or
intra-operative criteria. The patient selection criteria,
was left to the discretion of the treating physician and
followed established guidelines that IRE should be uti-
lized for locally advanced tumors that have failed initial
standard therapy and demonstrate persistent local disease.
General exclusion criteria, however, were any contrain-
dications for general anesthesia, extensive extra-organ
of ablation disease, or multifocal hepatic disease not
amenable to complete ablation.
IRE was performed using the Angiodynamics Nanoknife
system (Angiodynamics, Latham, NY). The Nanoknife
system consists of a computer controlled pulse gener-
ator that delivers 3000-volt pulses to the IRE probes.
The pulse voltages and duration are based on preclinical
studies [4,10] as well as clinical studies [10,11]. The pro-
cedure itself was similar to that described in our previ-
ous experience. Typically a minimum of 90 pulses is
delivered which last from 20 to 100 microseconds each.
The most common pulse duration is 90 microseconds,
although shorter durations (70 or 80 microseconds)
may be utilized in cases where high electrical resistance
is encountered. Treatment planning is based on pre-
operative imaging with CT scanning in which the tumor
dimensions and morphology are measured. Tumor di-
mensions are then measures and the number and spa-
cing of probes needed to create the desired ablation
zone based on the instruction for use are utilized. The
needles are multiple monopolar 19-gauge radio-opaque
probes, spaced 1.5 to 2.2 cm apart, were used depending
on the electroporation zone to be achieved.Access for the IRE procedure itself was percutaneous,
laparoscopic or open depending on the preference of
surgeon or interventional radiologist. CT guidance was
used for all percutaneous cases. General anesthesia with
deep neuromuscular blockade was used in all cases to
achieve paralysis to 0 twitches out of a train of 4. This
level of paralysis is needed to prevent patient movement
when the high voltage pulses are delivered. When multiple
probe arrays are utilized, a mechanical guide (spacer) is
employed to maintain proper spacing and alignment. The
probes are placed in a manner as to bracket the tumor,
rather than violate the tumor itself. The probes must
also be completely encased in tissue to prevent arcing.
Ablation technical success was defined as the ability to
successful deliver all planned pulses (at least 90) in ac-
cordance with size and dimension of the lesion, as well
as on at least 12 week axial scanning to demonstrate a
complete ablation without evidence of enhancement.
The definition of proximity to major vascular/biliary
structures or adjacent organs was defined as <5 mm in
distance.
Adverse events were recorded as per the established
Common Terminology Criteria for Adverse Events
(CTCAE), version 3.0. All complications were recorded
prospectively at all institutions. Follow up imaging was
performed at the time of discharge or with 2 weeks of
IRE therapy for safety evaluation and then at three-
month intervals. Early scans were obtained to look for
complications such as portal vein thrombosis. Imaging
was ordered by the treating physician and/or the multi-
disciplinary team caring for the patients. Post-ablation
recurrence was defined as persistent viable tumor as
defined by dynamic imaging in comparison to pre-IRE
scan or tissue diagnosis. Ablation success was defined
as the ability to deliver the planned therapy in the op-
erative room and at 3 months to have no evidence of
residual tumor as described above. The method of
evaluating local recurrence is the combination use of
both cross-sectional imaging, either a CT scan or MRI,
with or without PET scanning based on 1) the ability to
obtain a preoperative PET scan and 2) that the primary
lesion in question had PET activity. In cases where
preoperative PET scan was obtained and the lesion
was PET avid, persistent or recurrent PET avidity was
evidence for tumor recurrence. Specific cutoffs for
SUV to determine recurrence were not utilized. The
use of CT versus MRI imaging for follow-up was left
to the discretion of the treating physician. Dedicated
body-imaging radiologists, who were not blinded to
treatment, made radiologic interpretation of recur-
rence. As noted above, general radiologic criteria for
recurrence are new or persistent enhancement on
multi-phase imaging such as defined by the RECIST
criteria [12]. In cases where imaging was equivocal,
Martin et al. BMC Cancer 2014, 14:540 Page 3 of 9
http://www.biomedcentral.com/1471-2407/14/540biopsies were obtained at the discretion of the treating
physician.
Patient demographics, tumor characteristics, in hos-
pital outcomes, and local recurrence free survival were
examined. Continuous variables were summarized by
median and interquartile range (IQR) and compared
using the Wilcoxon-Mann–Whitney test while categor-
ical variables were summarized as count (percentage)
and analyzed using the chi-squared or Fisher’s exact
test, where appropriate. Local recurrence free survival
(LRFS) was determined from the time of ablation to
radiographic recurrence of the treated lesion. Patients
without evidence of recurrence were censored at the
time of last follow-up. Survival estimates were determined
according to the method of Kaplan and Meier, with sur-
vival curves compared by the log rank test. The relation
of target lesion size to LRFS was determined according
to Cox proportional hazards regression. To determine
whether there was an appropriate cutoff in tumor size
related to increased risk of LRFS, plots of martingale
residuals versus tumor size were examined as described
[13]. All statistical analyses were performed using SPSS
version 20.0, with p < 0.05 considered significant.
Results
A total of 107 consecutive patients underwent 117 IRE
procedures for tumors with vascular invasion from May
2010 to January 2012 from 7 centers. The median age
for this cohort was 62 years (mean 62.14, SD 12.2) with
a slight male predominance (50.4%). Diabetes was noted
in 20 (18.7%), and a significant history of cardiac disease
or pulmonary disease was seen in 8 (7.4%) patients each.
Tobacco use was prevalent in 35 (32.7%) while alcohol
abuse was found in 7 (6.6%) patients. Prior history of
hepatitis and pancreatitis was seen in 5 (4.7%) each. In
67 (57.2%) patients a history of prior abdominal surgery
was recorded. Median BMI was 26.9 and Karnofsky score
was 90%.
The access for IRE itself was either through a laparot-
omy in a majority of the cases (81–69.2%), or percutan-
eous CT guided in 32 (27%) and in 3 cases laparoscopy
was used for access. Majority of these were pancreatic
cancers (n = 84, 72%, 75 were performed through open
incision) and liver lesions constituted (n = 17, 14.5%)
with the rest being lung, kidney, mediastinal, pelvic and
prostate. Vascular structures proximity was confirmed
with pre-operative imaging (Figure 1). Liver lesions
were mostly colorectal hepatic metastasis (n = 11, 64%)
and pancreatic lesions were adenocarcinoma (n = 76,
90.4%) of the head and body. Among the 81 cases per-
formed by laparotomy there were 56 (69.1%) associated
major alimentary or hepatobiliary procedures. Pancre-
atic resections (total, Whipple, distal pancreatectomy)
comprised 23 (41%) of the major procedures andhepatectomy was done in 5 (9%). Enteric bypass and
bilio-enteric anastomosis were performed in 42 (77%)
and splenectomy in 7 (13.4%). Vascular reconstruction
was done in 14 cases (12%), with IRE performed prior
to resection in order to accentuate the surgical resection
margin. The decision to perform resection with IRE was
based intra-operatively if after surgical exploration and
dissection that an R1 resection would occur. IRE with
resection WAS NOT neither performed nor recom-
mended if an R2 resection would have occurred. Other
minor procedures included cholecystectomy (n = 17),
feeding access (n = 32) and celiac axis block (n = 10).
In a majority of the pancreatic lesions, vascular invasion
was to the portal vein (n = 70), to the superior mesenteric
artery or vein (n = 19), and the celiac axis (n = 6). For the
hepatic lesions, site of vascular invasion was the portal
and/or the hepatic veins.
A history of prior chemotherapy was seen in 82 (76.7%)
of patients, while radiation history was noted in 67 (63%)
patients. Other locally ablative procedures (RFA, ethanol,
microwave) had been previously tried in 11 (10.2%).
Hepatic arterial therapy such as TACE, Yt90 and bland
embolization was previously tried in 10 (9.3%).
Median size of the lesion in X, Y and Z-axis was 3 ×
2.5 × 2.75 cm each with a mean of 3.14 × 3 × 2.8 cm.
Mean and median total target size was 3.5 and 3.66 cm.
Median number of lesions ablated per patient was 2. Some
patients (10, 9.3%) had lesions that were numerous and
could not be counted accurately but were within a local-
ized ablation/ resection zone.
Median procedure time was 170 minutes (Mean:
174 + −97, IQR 109) while the actual probe placement
time was 10 mins (mean 15, IQR 5–20) and IRE deliv-
ery time per ablation was 28 (Mean 43.7, IQR 14–75)
minutes. Concurrent major abdominal procedures in
54 (50.4%) patients were associated with an increased
operative time (195 vs. 114 minutes, p < 0.0001) but
similar actual IRE delivery time (30 vs. 28 mins). Number
of pulses delivered was 90 and median number of probes
used per ablation was 3 with a mean of 3.35 with lesion
overlap seen in 51 (47.6%) cases. In 29 (31%) treatments
high current conditions were noted. In 7 the exact reason
for this was unknown but treatment was completed in a
majority of cases. Of the rest 22 the reason was either
retreatment area (which imparts high current situations)
or dense tissue with a minority due to sub-optimal probe
spacing.
Peri-procedural electroporation complications (defined
as within 90 days of IRE) were graded per CTCAE ver-
sion 3.0. There were a total 43/107 (40%) patients with
84 complications. The median complication grade was 2
(Table 1). There were no reports of procedure induced
dysrhythmias or major intraoperative bleeding in this co-
hort. Infectious complications included wound infection
Figure 1 A representative target lesion treated in this series with clear vascular invasion of the liver hilum in a patient with metastatic
colorectal cancer.
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Table 1 Factors affecting complications and high-grade complications after IRE (vascular invasion)
Complications











#Pts with PMH cardiac (n = 16pts) 6 (38%) 2 (13%) 0.4/0.7
#Pts with PMH Diabetes (26pts) 8 (31%) 2 0.009/0.05^ 4.0 1.4-11 0.007^
#Pts with Tobacco use (40 pts) 12 (30%) 4 0.2/0.5
#Pts with Pancreas IRE(59 pts) 30 (51%) 12 0.01/0.4^ 3.2 1.3-7 0.01^
#Pts with Open IRE (60 pts) 34 (57%) 13 0.00/0.00^ 5.8 1.4-11 0.02^
#Pts with Major Abdominal Procedure
(56 pts)
27 (48%) 15 0.03/0.2^ 0.8 0.3-1.8 0.5
#Pts with Radiation (67 pts) 21 (31%) 16 0.02/0.09^ 3.6 1.3-9 0.01^
#Pts with prior Intra-arterial Rx#
(21 pts)
2 (10%) 1 0.3/0.4
#Pt with prior ChemoRx (106 pts) 30 (28%) 11 0.8/0.4
Size of lesion > 3 cm 26 (36.1%) 9 (12.5%) 0.01/0.4^ 1.3 0.6-1.9 0.8
# Intra-arterial emboic therapy (SIRS, TACE, Bland), ^Higher risk of complications.
*Univariate analysis: 1st value is p value for complications, 2nd value is p for high-grade complications.
Martin et al. BMC Cancer 2014, 14:540 Page 5 of 9
http://www.biomedcentral.com/1471-2407/14/540(5/107, 4.7%), UTI (3/107, 2.8%), intra-abdominal ab-
scess (2/107, 1.9%) and pneumonia (1/107, 0.9%). Peri-
operative nausea and vomiting was seen in 7/107 (6.5%)
and 3/107 (2.8%) patient’s experienced prolonged ileus.
There were 3/107 (2.8%) patients with vascular compli-
cations namely, 1 case of portal vein thrombus, superior
mesenteric artery vein thrombus and one of hepatic ar-
tery thrombus, each. Two of these patients were on prior
anti-coagulation, one from extremity venous thrombosis
and the other from a old history (5 months prior to IRE)
of a pulmonary embolus. Significant biliary complications
included 2/107 (1.9%) cases of bile leak and 3/107 (2.8%)
biliary strictures. There were also 2/84 (2.4%) associated
pancreatic leaks and 3/84 (3.6%) cases of duodenal fistula
or leak. Transient liver failure was seen in 2/17 (11.9%)
and temporary renal failure was seen in 3/107 (2.8%).
High-grade complications were seen in 21 patients
with a high-grade complication rate of 17.9%. Compli-
cations were also divided into complications that were
related to the IRE or those related to associated proce-
dures. Related (attributable) complications were seen in
19 (16.2%) patients and high-grade attributable compli-
cations in 6 (5.1%).
Factors associated with complications were analyzed.
Diabetes was associated with an increased overall com-
plication rate (p = 0.009) and high-grade complication
rate (p = 0.05). Other medical co-morbidities including
prior cardio-pulmonary disease, tobacco and alcohol use
or prior abdominal surgery did not statistically affect the
complication rates or high-grade complications. There
was a higher incidence of complications with pancreatic
lesions (p value = 0.001). Laparotomy for access (n = 81,
p < 0.0001) and concurrent major abdominal procedures
(p = 0.02) significantly increased the complication rates.A prior history of radiation was predictive of complica-
tions (p value = 0.01) while percutaneous procedures
(p < 0.0001) and colorectal-hepatic metastases (CRHM,
p = 0.01) were associated with significantly lower rates.
Prior or recent chemotherapy, intra-arterial therapy and
previous abdominal surgery did not impact the complica-
tion rate. Complication rates were lower in patients who
underwent prior ablation or resections (p = 0.01) but this
was primarily due to the fact that these patients had liver
lesions.
A total of 2 (0.9% one related −0.4%) peri-operative
(within 90 days from IRE) deaths were seen in this study
group. One was felt to be possible related to IRE from
VTE, the other was not related to IRE and was from
urinary sepsis that was treated at an outside facility and
was decide to initiate hospice care only. Analysis was
performed and a diagnosis of pancreatic cancer and size
of the lesion (p = 0.01) was noted to be a significant as-
sociation whereas vascular invasion, size of the lesion
and prior chemotherapy was not noted to be statistically
significant factors.
After a median follow up of 29 months 39 (23%) had
recurrence of disease – local or distant. Mean time to
recurrence was 9.9 months in those patients that had
recurrence (local and remote), for liver median time
was 12 months (range 4 to 18 months) and for pan-
creas median was 16 months (range 3 to 36 months).
The recurrences were diagnosed with CT scan (n = 25),
MRI (n = 7) and PET CT (n = 7), for patients who had a
PET positive lesion pre-procedure, and 3 patients had
biopsy confirmation. Seven (5.9%) patients had evi-
dence of recurrence at their 3 month follow up imaging
and were called persistent disease and underwent
re-ablation.
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was 12.7 months for the entire cohort (Figure 2). Analysis
showed that presence of nodal disease, incomplete first
treatment, and adverse events at 1st treatment decreased
the recurrence free survival significantly. The tumor target
size was inversely associated with recurrence free survival
(b = 0.81, 95% CI: 1.6 to 4.7, p value = 0.02) but this did
not have a significant overall survival impact. Factors such
as organ of lesion, medical co-morbidities, access for IRE,
vascular invasion and prior adjuvant therapy had no
impact on RFS (Table 2).
Regarding mortality data and overall survival, 54 pa-
tients were deceased at the time of this analysis with a
median follow-up of 18 months. In all patients at follow
up, there has not been any evidence of vascular stricture
or narrowing of the vital structure in question. We have
seen 4 patients who developed portal/superior mesenteric
thrombosis during follow up (median time to thrombosis
was 6 months, range 3–10 months) with currently no
evidence of recurrent disease.
Analysis showed that factors associated with a worse
prognosis with respect to overall survival and mortality
included a diagnosis of pancreatic lesion (p = 0.00),
and the presence of serious adverse events in theFigure 2 Overall local recurrence free survival for all target lesions trefirst treatment (p = 0.00). Age had no impact on survival
(p value = 0.521), nor did a history of prior cardiac/
pulmonary disease (p value = 0.2), diabetes (p value = 0.9),
vascular disease (p value = 0.8), hypertension (p value = 0.2)
or a history of abdominal surgery (p value = 0.9).
The presence of a recurrence did not affect overall
survival in our study (p value = 0.26). Other factors that
did not affect overall survival were abnormal parenchyma
(p value = 0.9), nodal disease (p value = 0.8), peritoneal
disease (p value = 0.9), prior chemotherapy (p value = 0.8),
recent chemotherapy (p value = 0.7) and incomplete first
treatment (p value = 0.68).
A total of 12 patients had incompletely ablated tumors.
These observations were made of some of the incom-
pletely ablation patients:
 A presacral mass with persistent activity in the
neural foramen
 Inferior margin of lung mass
 Disease adjacent to RLL bronchus
 2 pancreatic body
 2 had good result following repeat IRE
 2 ablations could not be completed due to pacer
problems or mechanical difficulties.ated with IRE.






Open procedure 0.12 0.34 0.017 0.77
Incomplete ablation 0.18 0.386 0.1-1.5 1.53
MCRC* 0.05* 0.3 0.01 0.96
Pancreatic Adenocarcinoma 0.7 1.251 .322 4.85
Total Number of Lesions .510 .794 .401 1.57
Largest Dimension >3 cm^ 0.02^ 2.02 1.1 3.6
Chemotherapy^ 0.05^ 2.82 1.006 8.02
Radiation 0.1 0.5 0.2-1.2 1.2
*Lower risk of recurrence, ^Higher risk of recurrence.
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not have a significant impact on presence of incomplete
ablation.
Discussion
Irreversible electroporation is a relatively new and
evolving technique in soft tissue tumor ablations and
palliation [14]. Its advantages compared to RFA, micro-
wave, and cryotherapy are its non-thermal delivery
mechanism. When IRE is delivered appropriately it only
affects the target tissue and spares the surrounding
structures. Proteins, the extracellular matrix, and crit-
ical structures such as blood vessels and nerves are all
unaffected and left healthy by this treatment [2]. IRE ex-
pands the scope of palliative and/or definitive treatment
of lesions near major vascular/biliary/urinary structures
that in the past could only be treated with some forms
of external beam radiation therapy. The disadvantage is
the need for general anesthesia (deep paralysis) for its
safe and effective delivery [8].
This study is the single largest prospective evaluation
of IRE therapy in various organ sites and across access
techniques. Our data demonstrates acceptable safety and
optimal local disease control when used by the appropri-
ately trained physician.
The safety of IRE in this study group was evident with
this older population of a median age 62 years old,
which is comparable to other tissue ablation experiences
[15,16]. Cardiopulmonary disease was seen in 20.7% and
a history of tobacco use in 27%, which is higher than
with other reports of early RFA studies [17]. Even in the
population of patients with cardiac disease there was
not a single episode of cardiac toxicity (i.e. ventricular
arrhythmia, tachyarrythmias, or atrial fibrillation that
prevented effective energy delivery). In our study the in-
cidence of cirrhosis was lower than previously reported
but this is a reflection of the distribution of lesions among
other organs and a higher incidence of metastatic lesionsthat were ablated among liver lesions [15]. Majority of the
cases involved liver and pancreatic lesions (75), with the
access for IRE itself through a laparotomy (81 = 69.2%),
percutaneous CT, 32 (27%), or laparoscopy (N = 3). The
relatively large proportion of procedures done is more a
reflection of individual and institutional bias with some
centers having a significantly higher proportion of open
procedures. A significant number or patients (22%) had
other associated procedures, which also explains the
high number of patients who underwent open proce-
dures. This is in contradistinction to the early learning
curve analyses of RFA, which evaluated primarily percu-
taneous RFAs without any other associated procedures.
We chose to present our consolidated data to reflect the
individual preferences of the operators as well as to
evaluate this new procedure in its varied access and
organ-specific approaches.
As far as the distribution of liver lesions, there were
more metastases ablated than primary liver tumors,
which is in contrast with comparative non-western stud-
ies [15] but similar to recent western literature for RFAs
[18]. The mean number of lesions was also similar to
comparative studies. A significantly higher number of
tumors were noted to have a vascular invasion, which is
defined as being less than 5 mm of major vascular struc-
tures. This was much higher than most studies of similar
ablative techniques and is reflective of more advanced
disease and the advantage of IRE’s non-thermal action
that allows it to be used near vascular structures without
significant complications. Lesions with significant vascu-
lar involvement or involvement of biliary, collecting sys-
tem, bronchial tree and neural structures have long been
noted to be significant contraindication for traditional
thermal induced ablation techniques. IRE offers a suit-
able alternative and in this study we found a large num-
ber such anatomically hostile lesions. In spite of this
with respect to vascular complications, only one case of
portal vein thrombosis worsening in a patient with pre-
existing portal vein thrombus was noted with a vascular
complication rate of 1.3% (1/77 cases) in patients with
vascular invasion and 0.6% in this cohort. This rate is
significantly lower than similar studies in RFA despite
the low rate of vascular proximity in those lesions, dem-
onstrating the safety of IRE in this situation [15,18].
A total of 452 lesions were ablated with median number
of ablations per treatment being 2 with mean dimensions
of 2.49 × 2.24 × 2 cm. The procedure time at 152 mi-
nutes was significantly longer than most in relatable
thermo-ablative studies and similar to IRE studies, des-
pite the high number of associated procedures [17]. De-
livery of 90 pulsed treatments with an average of 2
mins per treatment lends to a significantly longer treat-
ment time than RFA and microwave, and is one of the
disadvantages of IRE.
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lations, 5 of which were subsequently ablated adequately.
In the other cases it was felt by the operator that lesion
was in an anatomically unfavorable position, leading to
poor lead placement and incomplete delivery. This is a
high percentage of lesions that were either incompletely
ablated or found unsuitable. As noted in our previous
experience, pre-operative dynamic imaging which is used
to plan these treatments, sometimes underestimates the
degree of involvement with surrounding structures or
the size, especially for pancreatic and retroperitoneal
structures. A majority of our patients had a post-procedure
imaging and one at 3 months to evaluate the response to
treatment and 10.1% of patients had evidence of persistent
tumor on repeat imaging. 11 of who underwent re-ablation
successfully. This is a rate that is similar to initial RFA
learning curve experiences [18], but most studies did
not report this rate.
The results that we have presented compare favorable
to High Intensity Focus Ultrasound (HIFU), which con-
tinues to report an ablation success of 91%, 79%, and 50%
from the most current series reported in large number of
patients [19-21]. That inferior ablation success reported
above, coupled with ablation recurrences of 35%, 21%, and
28%, make IRE a potential more superior local palliative
option with better ablation success and long term disease
control.
The complication rate in this cohort was 29.3%, which
is significantly higher than similar studies (reported
complication rates of (6-16%) in RFA and microwave.
Complications were also graded as related to the pro-
cedure, unrelated, possibly related, and related to asso-
ciated procedures. For purposes of analysis IRE related
complications were all complications that were related,
possibly related and those without any good causative
associations. Analysis of IRE related complications took
this rate down to 13.3%, which is more congruent with
similar precedents. On comparing only percutaneous
IRE and their complication rates, the complication rate
was 6.8%, which is similar to precedents. High-grade
complications were noted in 16 (10.6%) with 6 (4%) IRE
related complications attributable to IRE. No specific
gradation of complications and auditing of re-interventions
were seen in similar studies, such that a comparison could
not be made. There were no cases of cardiac arrhythmias
in this study, which is lower than previous literature [17].
Local recurrence was seen in 10.7% of patients ablated
and is comparable to similar studies. A LRFS of 9.7 months
is hard to interpret with this anatomically and biologically
diverse lesion, but in view of the nature of uniformly ad-
vanced disease and it is congruent with other studies.
These lesions were larger lesions with greater numbers of
anatomically hostile features including vascular invasion
and we think that this is an acceptable recurrence rategiven the mean follow up period. Larger lesions, advanced
local disease (nodal and peritoneal disease) led to greater
recurrences. As expected an incomplete first treatment
(even if subsequently addressed) as well as adverse events
at ablation led to shortening of LRFS.Conclusions
IRE is a new non-thermal based electroporation technique
of tissue ablation, which acts by changing the membrane
properties allowing cell death. Accurate mapping and
image-based guidance can lead to precisely targeted tissue
destruction. Since it is not thermal based, it avoids the
“sump” limitations and can be used for lesions abutting
thermo-sensitive or thermal-limiting structures such as
vascular, biliary, urinary and nervous structures. A multi-
center analysis of these patients, with a variety of lesions
and access techniques demonstrated that IRE could be
successfully performed in a majority of the cases without
major adverse events. As expected tumor biology, with re-
spect to the organ of origin of the lesion was a significant
factor with respect to mortality and overall survival. Insti-
tutional and individual preferences colored the mode of
access and other associated procedures that were per-
formed simultaneously. With time, more complex treat-
ments of larger lesions and lesions with greater vascular
involvement was performed without a significant increase
in adverse effects or impact on LRFS. The evolution of this
procedure over time in this initial experience demon-
strates the safety profile of IRE and the relative speed of
graduation to more complex lesions in a relatively short
span of time.
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